# Magle Chemoswed Holding > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/maglechemoswedholding). ## Overview Magle Chemoswed Holding AB is a Swedish life-science group based in Malmö with operations centered on pharmaceutical chemistry and drug-delivery technologies. Through its subsidiaries, it develops and manufactures APIs, biopolymer-based healthcare products, and diagnostic-related products, while also providing contract development, manufacturing, and laboratory services. ## Products & services • API development and manufacturing • Clinical-trial and commercial drug products • CDMO services for biopolymers and dextran • Degradable starch microsphere (DSM) products • Contract laboratory and analytical services • Packaging, labelling, and logistics support - **Pharmaceutical CMO/CDMO** (45%) — Development and manufacturing of APIs and finished pharmaceutical products for clients. - **Biopolymers and dextran solutions** (25%) — CDMO and manufacturing services focused on dextran and biopolymer-based healthcare products. - **Proprietary DSM and dextran products** (20%) — Direct sales and distribution of degradable starch microsphere and dextran products. - **Contract laboratory and consulting services** (10%) — Analytical development, material characterization, and solid-state analysis services. - API development and manufacturing - Clinical-trial and commercial drug products - CDMO services for biopolymers and dextran - Degradable starch microsphere (DSM) products - Contract laboratory and analytical services - Packaging, labelling, and logistics support ## Customers Customers include pharmaceutical companies that need development, scale-up, and manufacturing support for APIs and finished dosage forms. The group also serves medical and diagnostics customers buying proprietary DSM, dextran, and biopolymer-based products, as well as clients needing analytical and material-characterization expertise. Its offering is designed for customers that want regulated, integrated support from early development through commercial supply. - **Pharmaceutical developers and manufacturers** (primary) — Buy API development, formulation, manufacturing, packaging, and logistics support for drug programs. - **Clinical-trial sponsors and clinics** (secondary) — Buy trial-ready pharmaceutical products and related manufacturing services for study use. - **Medical device and diagnostics customers** (primary) — Buy DSM, dextran, and biopolymer-based products for medical applications. - **Pharma and biotech R&D clients** (secondary) — Buy contract laboratory, material characterization, and process-development services. - Pharmaceutical companies outsourcing API and formulation work - Clinical-trial sponsors needing small-batch finished products - Medical and diagnostics customers buying DSM and dextran products - Biopolymer customers seeking contract manufacturing and supply - Clients needing analytical chemistry and solid-state expertise ## Geography The group is headquartered in Malmö, Sweden, with core operations also in Berlin, Germany and Køge, Denmark. Reported revenue is split between Sweden, Europe excluding Sweden, and other territories, showing a business that sells both within Europe and internationally. Its manufacturing and development footprint is therefore important to regulatory access, customer proximity, and supply-chain execution. - **Sweden** (15.8%) — Estimated from reported revenue mix - **Europe excluding Sweden** (24.6%) — Estimated from reported revenue mix - **Other territories** (59.6%) — Broad international bucket; country mix not disclosed - Headquartered in Malmö, Sweden - Core operations in Berlin and Køge - Revenue reported across Sweden, Europe ex Sweden, and other territories - International sales matter for DSM and product distribution - Multi-site footprint supports regulated manufacturing and delivery ## Strategy The group’s strategy is built around integrated pharmaceutical development and manufacturing, combining internal R&D with regulated production capabilities. It also emphasizes proprietary DSM and dextran technologies, using direct sales, distributors, and licensing to extend the reach of its own products while keeping contract manufacturing as a recurring base. The business is focused on allocating resources toward the programs and product lines with the clearest commercial and clinical potential. - **Advance proprietary DSM and dextran products** (medium-term) — Own products can create differentiated demand and licensing value beyond pure contract manufacturing. - **Maintain integrated CDMO execution** (short-term) — End-to-end development and manufacturing capabilities support customer retention and switching costs. - **Expand distribution and outlicensing pathways** (medium-term) — Partners can broaden market reach while reducing the capital burden of commercialization. - Integrate development, manufacturing, and logistics in one platform - Advance DSM and dextran technologies toward commercialization - Use direct sales and distributors for proprietary products - Retain contract manufacturing as a recurring revenue base - Focus resources on programs with the strongest commercial potential ## Risks The business depends on successful development, regulatory compliance, and customer adoption of specialized pharmaceutical and biopolymer products. It also faces execution risk from integrating acquired businesses and from the technical and quality requirements of regulated manufacturing, where delays or failures can affect revenue and asset values. Like other pharma CDMOs, it is exposed to customer concentration, product-development uncertainty, and valuation risk in acquired intangibles and inventory. - **Regulatory and quality compliance** [high] — The company manufactures APIs and finished products for clinical and commercial use under licenses and approvals. - **Development and commercialization risk** [high] — DSM, dextran, and other proprietary programs depend on successful technical and clinical progress. - **Integration and acquisition risk** [high] — The group has a portfolio of acquired businesses and assets that must be integrated operationally and financially. - **Customer and project concentration** [medium] — CDMO revenue can depend on a limited number of projects, programs, or distributors at any time. - **Geographic and currency exposure** [medium] — Operations and sales span Sweden, Germany, Denmark, and other territories. - Regulatory and quality failures can disrupt manufacturing and approvals - Development projects may not reach commercialization - Customer demand can be lumpy across clinical and commercial programs - Acquired assets and intangibles can require impairment - International sales expose the group to currency and market risk ## Accounting Reported results are sensitive to revenue mix across product sales, services, and royalties, which can shift quarter to quarter as projects move through development and commercialization. The group also carries significant judgment in goodwill, intangible assets, and acquired plant and equipment, making impairment and depreciation assumptions important to reported earnings and equity. Because it uses a multi-entity structure and has acquisition accounting history, investors should watch consolidation eliminations, fair-value allocations, and any noncash adjustments tied to acquired assets. - **Revenue recognition by stream** — Affects quarterly revenue mix and margin comparability - **Goodwill and intangible asset impairment** — Can materially affect earnings and equity - **Purchase price allocation and depreciation** — Influences depreciation, amortization, and book value - **Consolidation eliminations** — Affects reported group revenue and expenses - Revenue mix includes product sales, services, and royalties - Quarterly comparability can shift with project timing and deliveries - Goodwill and intangibles require impairment and useful-life judgment - Acquisition accounting affects asset values and depreciation - Consolidation eliminations reflect intercompany activity across entities --- *Last updated: 2026-08-11T04:04:54.063437+00:00*